Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan

MLA

Tsai-Yuan Hsieh, et al. Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan. Sept. 2021. EBSCOhost, https://doi.org/10.21203/rs.3.rs-882398/v1.

APA

Tsai-Yuan Hsieh, Tzong-Hsi Lee, Mei Hsuan Lee, Ching-Chu Lo, Chien-Neng Kao, Ming-Lun Yeh, Chun-Ting Chen, Han Chieh Lin, Chia-Chi Wang, Te-Sheng Chang, Chi-Chieh Yang, Yi Hsiang Huang, Wang-Long Chuang, Jee-Fu Huang, Jui-Ting Hu, Chih-Lin Lin, Chun-Jen Liu, Szu-Jen Wang, Chien-Wei Huang, … Chia-Yen Dai. (2021). Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan. https://doi.org/10.21203/rs.3.rs-882398/v1

Chicago

Tsai-Yuan Hsieh, Tzong-Hsi Lee, Mei Hsuan Lee, Ching-Chu Lo, Chien-Neng Kao, Ming-Lun Yeh, Chun-Ting Chen, et al. 2021. “Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan,” September. doi:10.21203/rs.3.rs-882398/v1.